2020 American Transplant Congress
Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis
1Inha University, Incheon, Korea, Republic of, 2Keimyung University, Daegu, Korea, Republic of
*Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the…2020 American Transplant Congress
Impact of Nursing Education on Organ Donation
1Northwell Health, Manhasset, NY, 2Northwell Health, New Hyde Park, NY
*Purpose: Organ transplantation is the gold-standard for patients with end-stage organ disease. For organ donation to occur, potential donors need to be identified and referred…2020 American Transplant Congress
Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with…2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…2019 American Transplant Congress
Implementation of Novel Machine-Learning Techniques to Tailor Donornet® Organ Offers to Center and Surgeon Preference
Transplant Center, Massachusetts General Hospital, Boston, MA
*Purpose: Real-time communication regarding organ placement is critical. For this purpose, UNOS launched DonorNet®, a computerized allocation algorithm, to aid and facilitate organ placement. However,…2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…2019 American Transplant Congress
Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease
*Purpose: Diabetes is a growing public health problem, and diabetes kidney disease (DKD) is the most prevalent chronic kidney disease and the major cause of…2019 American Transplant Congress
Exploration of the Stanford Integrated Psychosocial Assessment for Transplant with Psychosocial and Medical Outcomes in Kidney/Kidney-Pancreas Transplant Recipients
*Purpose: The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a psychometric instrument designed to improve organ transplant patient selection. However, limited studies have been…2019 American Transplant Congress
A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Background: Utilization of direct-acting oral anticoagulants has become a preferred method for chronic anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).…2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »